课题基金 / 基金详情

Diversity Supplement: Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury

Diversity Supplement: Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
多样性补充剂:引导色氨酸免疫代谢改善肝脏缺血再灌注损伤
批准号:
10632561
负责人:
Benjamin George Keselowsky
金额:
$3.75万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-01 至 2025-12-31

项目摘要

项目成果

Benjamin George Keselowsky的其他基金

相似基金

相关文献

中文摘要
翻译
联系PD/PI:Keselowsky,Benjamin G 项目摘要/摘要 许多不同的疾病状态和手术干预导致了一段时间的不充分 组织/器官供血(即缺血),当血流量减少时,会导致再灌注损伤 恢复,称为缺血再灌注损伤(IRI)。IRI导致局部炎症,细胞死亡, 过度的组织破坏和可能的器官衰竭。移植就是这样的例子, 创伤、心肌梗死、中风,尤其是IRI是肝功能障碍的主要原因。 以及肝脏手术后的衰竭。不幸的是,目前临床上还没有可用的治疗方法。 练习解决IRI,其中主要问题是有害的全身副作用和毒性 现有药物的价值。 为了解决这个问题,我们正在创新一种新的治疗技术,旨在通过编程 免疫细胞通过引导色氨酸进入代谢状态阻止过度炎症 通过将一种酶送入循环而进行的新陈代谢。这代表了一种新的反 炎症/免疫抑制生物药物,可能限制全身毒性/副作用 影响,并有可能显著减少免疫损害。缺乏治疗选择 肝脏IRI和体内初步数据目录有力地支持了基本原理 IDO作为一种创新的新型抗炎剂的前景,使这一提议具有非常重要的意义。 展望未来,成功将打开机会,扩大到其他消炎药 例如,用于移植的供体移植物的预处理。 项目摘要/摘要第6页
英文摘要
Contact PD/PI: Keselowsky, Benjamin G Project Summary/Abstract Many different disease states and surgical interventions result in a period of inadequate tissue/organ blood supply (i.e., ischemia), that result in reperfusion injury when blood flow is restored, known as ischemia-reperfusion injury (IRI). IRI causes local inflammation, cell death, excessive tissue destruction and possible organ failure. Examples are found in transplantation, trauma, myocardial infarction, stroke, and in particular, IRI is a main cause of liver dysfunction and failure after liver surgery. Unfortunately, there are currently no therapies available in clinical practice addressing IRI, where a major problem is the harmful systemic side effects and toxicities of existing drugs. To address this problem, we are innovating a new therapeutic technology aiming to program immune cells toward a metabolic state blocking excessive inflammation by directing tryptophan metabolism through delivery of an enzyme into circulation. This represents a new class of anti- inflammatory/immunosuppressive biologic drug, with potential to limit systemic toxicities/side effects, and with potential to be significantly less immunocompromising. Lack of treatment options for liver IRI and a catalog of in vivo preliminary data strongly supporting the foundational rationale of IDO as an innovative new anti-inflammatory agent, make this proposal highly significant. Looking to the future, success would open opportunity to expand to other anti-inflammatory applications, for example, pre-conditioning donor grafts for transplantation. Project Summary/Abstract Page 6
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
  • 批准号:
    10595020
  • 项目类别:
  • 资助金额:
    $65.42万
  • 财政年份:
    2022
  • 负责人:
    Benjamin George Keselowsky
  • 依托单位:
Directing Tryptophan Immunometabolism to Ameliorate Liver Ischemic-Reperfusion Injury
  • 批准号:
    10444213
  • 项目类别:
  • 资助金额:
    $67.64万
  • 财政年份:
    2022
  • 负责人:
    Benjamin George Keselowsky
  • 依托单位:
Functionalized Enzyme Treatments for Dual-Targeting of Inflammation in Spinal Cord Injury
  • 批准号:
    10284992
  • 项目类别:
  • 资助金额:
    $41.0万
  • 财政年份:
    2021
  • 负责人:
    Benjamin George Keselowsky
  • 依托单位:
Tissue-Targeted Enzyme for Localized Tryptophan Catabolism to Direct Subcutaneous and Oral Mucosal Inflammatory Responses
  • 批准号:
    9752509
  • 项目类别:
  • 资助金额:
    $46.42万
  • 财政年份:
    2017
  • 负责人:
    Benjamin George Keselowsky
  • 依托单位:
海外基金